Previous Article | Next Article 
Infection and Immunity, August 2001, p. 5138-5150, Vol. 69, No. 8
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.8.5138-5150.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Enhanced Susceptibility to Pulmonary Infection with
Burkholderia cepacia in
Cftr
/
Mice
Uma
Sajjan,1
George
Thanassoulis,2,3
Vera
Cherapanov,2,3
Annie
Lu,1
Carola
Sjolin,1
Brent
Steer,1
Yi Jun
Wu,1
Ori D.
Rotstein,4
Geraldine
Kent,1
Colin
McKerlie,5
Janet
Forstner,1 and
Gregory P.
Downey1,2,3,*
Research Institute, The Hospital for Sick Children,
Toronto, Ontario M5G 1X8,1 Division of
Respirology, Department of Medicine,2 and
Department of Surgery,4 The University
of Toronto, Toronto, Ontario M5S 1A8, Comparative Research,
Sunnybrook and Women's College Health Sciences Center, Toronto,
Ontario M4N 3M5,5 and The Toronto
General Hospital Research Institute of the University Health
Network, Toronto, Ontario M5G 2C4,3
Canada
Received 5 February 2001/Returned for modification 14 March
2001/Accepted 2 May 2001
 |
ABSTRACT |
Progressive pulmonary infection is the dominant clinical feature of
cystic fibrosis (CF), but the molecular basis for this susceptibility
remains incompletely understood. To study this problem, we developed a
model of chronic pneumonia by repeated instillation of a clinical
isolate of Burkholderia cepacia (genomovar III,
ET12 strain), an opportunistic gram-negative bacterium, from a case of
CF into the lungs of Cftr m1unc
/
(Cftr
/
) and congenic
Cftr+/+ controls. Nine days after the last
instillation, the CF transmembrane regulator knockout mice
showed persistence of viable bacteria with chronic severe
bronchopneumonia while wild-type mice remained healthy. The
histopathological changes in the lungs of the susceptible Cftr
/
mice were characterized by
infiltration of a mixed inflammatory-cell population into the
peribronchiolar and perivascular spaces, Clara cell hyperplasia, mucus
hypersecretion in airways, and exudation into alveolar airspaces by a
mixed population of macrophages and neutrophils. An increased
proportion of neutrophils was observed in bronchoalveolar lavage fluid
from the Cftr
/
mice, which, despite an
increased bacterial load, demonstrated minimal evidence of activation.
Alveolar macrophages from Cftr
/
mice
also demonstrated suboptimal activation. These observations suggest
that the pulmonary host defenses are compromised in lungs from animals
with CF, as manifested by increased susceptibility to bacterial
infection and lung injury. This murine model of chronic pneumonia thus
reflects, in part, the situation in human patients and may help
elucidate the mechanisms leading to defective host defense in CF.
 |
INTRODUCTION |
Cystic fibrosis (CF) is an autosomal
recessive disease caused by mutations in the gene encoding the CF
transmembrane regulator (CFTR), a transmembrane glycoprotein
responsible for chloride conductance in epithelial cells. Progressive
pulmonary disease is the dominant clinical feature of CF and accounts
for 95% of the morbidity and mortality (11, 51). Despite
intensive study, the mechanisms responsible for this enhanced
susceptibility to infection remain incompletely understood and a source
of controversy. Absence or dysfunction of CFTR leads to alterations in
the microenvironment of the lung that are manifest early in life as
inflammation of the distal airways (25), but whether this
is cause or consequence of infection remains controversial
(4). Reported abnormalities in the pulmonary environment
in the lungs of animals with CF include altered fluid and ionic fluxes
across the respiratory epithelium, excessive luminal mucus, diminished
mucociliary clearance, altered patterns of epithelial surface
glycosylation, and diminished activity of bactericidal factors such as
lysozyme, lactoferrin, defensins, and cathelicidins (6, 11, 18,
34, 41, 54, 61). The relative contributions of these factors to
airway infection in CF remain unknown.
Whatever the proximate cause of the susceptibility to infection,
the milieu of the lungs of animals with CF provides a favorable niche
for bacterial infection with certain opportunistic pathogens such as
Staphylococcus aureus and eventually resistant gram-negative organisms such as Pseudomonas aeruginosa. A subpopulation
consisting mainly of adolescent and adult patients also develop chronic
infection with resistant gram-negative bacterium Burkholderia
cepacia. The clinical outcome after acquisition of B. cepacia is variable, ranging from an asymptomatic culture-positive
state to a devastating syndrome of fatal necrotizing pneumonia and
septicemia (cepacia syndrome) (12, 16, 60). Why CF
predisposes patients to acquisition of B. cepacia is
incompletely understood. Host lung factors such as underlying lung
damage (16, 23), repeated exposure (15, 28, 37,
53), and specific bacterial factors, such as presence of cable
pili (46-48), production of extracellular enzymes
(30, 39), and the ability of some strains of B. cepacia to replicate intracellularly (3, 33, 43), all
appear to contribute to the propensity to persistent infection.
One feature that has thwarted the identification of virulence
properties is that B. cepacia is not a single clonal strain. Rather, it consists of a complex of strains that belong to one of five
or more genetic groups or genomovars (2, 62). The most
common groups cultured from sputa from CF patients are
genomovars II, III, and IV (30). (Genomovars II and IV
have been renamed Burkholderia multivorans and
Burkholderia stabilis, respectively [2, 62].)
Within genomovar III, the highly transmissible strain (the ET12 strain
[59]) expresses cable pili and its associated 22-kDa
adhesin (46, 48). This is the strain most commonly cultured from CF patients in Canada and the United Kingdom and is the
one most commonly associated with the cepacia syndrome (17,
32). Since this strain was shown to bind most strongly to
mucins, to epithelial cells, and to tissue sections from lungs of CF
patients (45, 47, 49), we have used this strain to develop an animal model of lung infection.
Given the difficulties in studying the pathogenesis of bacterial
infection in CF patients, murine models have been used as an
experimental model system. CFTR-deficient (knockout) mice have been
used to study experimental infection (7, 8, 10, 14, 19,
35). While these studies have provided important insights into
the pathogenesis of CF lung disease, many have focused primarily on the
acute responses to infection and some have relied on the use of
agar-entrapped bacteria (14, 19) to assure the retention of bacteria in the lungs by mechanical means. In general, compared to
wild-type mice, Cftr
/
mice demonstrate
decreased bacterial clearance, an excessive inflammatory response, and
significant mortality when challenged with pathogenic organisms
including S. aureus, P. aeruginosa, and B. cepacia, indicating that the absence of CFTR may increase the
susceptibility of mice to infection with these opportunistic pathogens.
In contrast, several recent studies have found that Cftr
/
mice were able to clear P. aeruginosa from their lungs as well as wild-type controls
(7, 8, 35). These discrepancies may be explained by the
complex genetic backgrounds of the mouse strains used, including the
presence of alternative chloride channels, the different methods of
bacterial delivery to the lungs, dietary factors, and the nutritional
state of the mice. Thus, the relationship between CFTR expression, the
pulmonary inflammatory response, and bacterial clearance remains uncertain.
Our goal was to develop a model of chronic pulmonary infection with
B. cepacia in mice with CF without the need for bacterial entrapment or use of immunosuppressive agents. We hypothesized that the
ineffective inflammatory responses observed in CF patients would be
manifest in this model and that the propensity for enhanced pulmonary
inflammation and injury would also depend on bacterial virulence. To
investigate the latter, we used two strains of B. cepacia,
one clinical isolate from the highly transmissible genomovar III (ET12)
strain and an environmental type strain isolated from onion rot (ATCC
25416; genomovar I), to compare their virulence properties in mice. We
compared the pulmonary inflammatory response to repeated administration
of bacteria in both Cftr
/
and
Cftr+/+ mice to judge the role of the
Cftr
/
phenotype in enhancing
susceptibility to lung infection.
 |
MATERIALS AND METHODS |
Bacterial strains and growth conditions.
A clinical isolate
of B. cepacia BC7 was obtained from sputum of a CF patient
at the Hospital for Sick Children in Toronto, Ontario, Canada. This
patient died with the cepacia syndrome within 1 month of acquisition of
the organism (45). Isolate BC7 is an ET12 strain, belongs
to genomovar III, has been classified as randomly amplified polymorphic
DNA type 2, carries the epidemic DNA marker designated BCESM, and
expresses surface cable pili (32, 46, 47). ATCC 25416 is
an environmental type strain isolated from onion rot, belongs to
genomovar I, and was purchased from the American Type Culture
Collection (Manassas, Va.) (32). Both isolates were stored
at
80°C. In preparing the inoculum for infecting animals, B. cepacia isolates were subcultured on brain heart infusion (BHI)
agar (Becton Dickinson Co., Cockeysville, Md.) and single colonies were
inoculated into 10 ml of tryptic soy broth (Difco Labs, Detroit, Mich.)
and grown overnight on an orbital shaker at 150 rpm at 37°C. Bacteria
were harvested by centrifugation at 6,000 × g for 10 min, and the bacterial pellet was suspended in sterile
phosphate-buffered saline (PBS) to a concentration of
109 CFU/ml. Viable bacterial counts were measured
by plating serial dilutions of bacteria on B. cepacia
selective agar (20) or BHI agar plates.
Experimental animals.
Long-surviving liquid-fed
Cftrm1UNC knockout (i.e.,
Cftr
/
) mice (24) and their
littermate wild-type Cftr+/+ controls, age
6 to 8 weeks, were utilized in the study. Wild-type mice were also
liquid fed during the experimental protocol to minimize differences
that could occur due to diet or nutritional status. Genotyping was done
as previously described (56), and only homozygotes
(Cftr+/+ and
Cftr
/
) were used in this study. Mice
were divided into three groups. In group 1, comprising 12 Cftr+/+ and 11 Cftr
/
mice, animals received only PBS.
In group 2, comprising 12 Cftr+/+ and 19 Cftr
/
mice, animals were infected with
isolate BC7. In group 3, comprising four
Cftr+/+ and six
Cftr
/
mice, animals were infected with
isolate ATCC 25416. Experiments were carried out according to protocols
approved by the animal care committee at the Hospital for Sick
Children. The animals were housed in a clean conventional area free of
pathogens in sterile microisolator cages until they reached the
required age. Littermate wild-type controls were maintained under
identical conditions. Mice were transferred 24 h before the start
of an experiment to a containment unit and housed in the same area
throughout the experiment.
Infection of mice.
Mice were anesthetized lightly using the
inhalant anesthetic enflurane. To achieve intrapulmonary delivery, PBS
(50 µl) or PBS containing B. cepacia
(107 CFU) was instilled dropwise intranasally and
allowed to be aspirated into the lungs. To ensure maximum delivery of
bacteria into the lungs, mice were held with their mouths closed during
the instillation. This technique was based on the results of
preliminary experiments using
99mTc-labeled bovine serum albumin, which
demonstrated maximum pulmonary delivery with minimal delivery to the
gastrointestinal tract (data not shown). Additional studies using nasal
instillation of a suspension of iron-dextran followed by Pearl's
Prussian blue staining of the fixed and sectioned lungs demonstrated
that the suspension was distributed equally to all lobes of the lungs
and reached the alveoli (data not shown). Bacteria were administered on
days 0, 3, 6, and 9, and the mice were sacrificed on day 18 by
intraperitoneal injection of 0.3 ml of a 6.5-mg/ml solution of sodium
pentobarbital and exsanguination.
BAL.
Bronchoalveolar lavage (BAL) was conducted by
instilling three 1-ml aliquots of sterile PBS via a cannula
placed into the trachea and secured with ligatures. The average volume
of BAL fluid recovered was 2.6 ml. The concentration of cells in BAL fluid was determined using a hemocytometer. Fifty microliters of BAL
fluid was sedimented in a cytocentrifuge (Shandon Inc., Pittsburgh,
Pa.), fixed with methanol, and stained using a modified Wright-Giemsa
stain (Diff-Quick; Dade Diagnostics, Aquanda, Puerto Rico). The
percentage of each cell type was determined by counting a total of 300 cells/slide. The cells in the remaining BAL fluid were sedimented by
centrifugation and saved for analyses as outlined below. The
supernatant was immediately mixed with a protease inhibitor cocktail
(Boehringer Mannheim, Toronto, Ontario, Canada) and stored on ice until
used. Lungs, blood, and spleens were also collected for analyses.
Flow-cytometric analysis.
Cells obtained from the BAL fluid
were incubated with 20% fetal bovine serum (FBS) for 30 min and washed
with 10% FBS in PBS prior to addition of antibodies. As indicated in
the legend to Fig. 6, cells were labeled with fluorescein
isothiocyanate (FITC)-conjugated anti-CD11c and
phycoerythrin-conjugated anti-major histocompatibility complex class II
(MHC-II) (BD-Pharmingen Canada, Mississauga, Ontario, Canada) in 10%
FBS in PBS, washed, and fixed with 1.6% paraformaldehyde. Two-color
flow cytometry was performed using a FACScan flow cytometer equipped
with CELLQuest software (Becton Dickinson, San Jose, Calif.).
Macrophages were identified using a combination of light-scattering
properties and surface expression of CD11c. The level of MHC-II surface
expression was quantified on this population of cells. For assessment
of oxidant production, cells were incubated with
10
5 M dihydrorhodamine (Molecular
Probes, Eugene, Oreg.) for 5 min at 37°C followed by fixation with
1.6% paraformaldehyde. The fluorescence of the reduction product,
rhodamine 1-2-3, was evaluated by one-color flow cytometry as a measure
of oxidant production as previously described (63).
Surface expression of F4/80, CD4, and CD8 on BAL cells was determined
using the appropriate primary conjugated antibodies (BD-Pharmingen
Canada). For all analyses, a minimum of 10,000 cells were measured per
condition, and all values are expressed as relative fluorescence
indices based on the geometric mean of the gated populations as
described above.
Determination of bacterial persistence.
BAL fluid, blood,
lungs, and spleens were individually collected from each animal under
aseptic conditions. Tissues were homogenized in 2 ml of sterile PBS
using a tissue homogenizer (Polytron PT10/35; Brinkman Instruments,
Mississauga, Ontario, Canada). Serial 10-fold dilutions of tissue
homogenates, BAL fluid, and blood were plated on blood agar and/or
B. cepacia selective agar plates. The number of CFU was
determined after 72 h of incubation at 37°C. Identity of the
bacteria recovered from animals was routinely confirmed by the Clinical
Microbiology Department at the Hospital for Sick Children. When mice
were infected with isolate BC7, a PCR with gene-specific primers for
cblA (48) was used to confirm the identity of
the recovered bacteria.
Histopathological evaluation.
Lungs were inflated with air,
flushed via the pulmonary artery with PBS followed by 5%
paraformaldehyde, and then fixed by immersion in 10% neutral buffered
formalin overnight. Tissues were processed and embedded in paraffin,
and 5-µm-thick sections were stained with hematoxylin and eosin,
periodic acid-Schiff (PAS), Giemsa, or trichrome stain. Slides
were blinded for genotype of the mice and the treatment given and
scored by a veterinary pathologist using a semiquantitative scale in
the range of 0 to 5 (10). Zero on this scale indicated no
inflammatory change, while 5 represented severe inflammation with
tissue destruction.
Immunofluorescence detection of B. cepacia in
lungs and BAL cells.
Lung sections from each mouse were
deparaffinized and rehydrated in graded alcohol and water. Sections
were heated in 10 mM sodium citrate buffer, pH 6.0, for 90 s at
121°C under pressure for antigen retrieval (52).
Sections were washed with water, equilibrated in Tris-buffered saline
(10 mM Tris buffer [pH 7.5] containing 0.15 M NaCl) and blocked with
5% normal donkey serum for 2 h at room temperature.
Sections were incubated overnight at 4°C with polyclonal antibody
R418 (1:1,000 dilution), which recognizes B. cepacia of all
genomovars (44), and washed to remove excess antibody, and
the bound antibody was detected by anti-rabbit immunoglobulin G
conjugated with Cy3 fluorophore (1:250 dilution) (Jackson
ImmunoResearch Lab, West Grove, Pa.). Sections were
counterstained with Mayer's hematoxylin. When BAL fluid was used,
cells were harvested by cytocentrifuge onto a slide, fixed in cold
methanol, blocked with 5% normal donkey serum, and treated with
anti-B. cepacia antibody R418 as described above.
Measurement of cytokines by ELISA.
The levels of murine
tumor necrosis factor alpha (TNF-
), KC/N51, gamma interferon
(IFN-
), and macrophage inflammatory protein 2 (MIP-2) in BAL fluid
were measured by a sandwich enzyme-linked immunosorbent assay (ELISA)
according to the manufacturer's instructions (R&D Systems,
Minneapolis, Minn.). All samples were analyzed in triplicate in a
blinded fashion and compared with known standards.
EMSA.
Nuclear levels of transcription factors NF-
B and
CREB were measured by electrophoretic mobility shift assays (EMSA)
essentially as described previously (38). In brief, 5 µg
of protein from nuclear extracts of whole lungs was preincubated with
nonspecific DNA competitor poly(dI-dC) (5 mg; Pharmacia, Piscataway,
N.J.) for 10 min at room temperature. The
32P-radiolabeled probe containing the NF-
B3
site of the murine TNF-
gene promoter (mTNF
B3) was incubated
for an additional 20 min at room temperature. DNA-protein complexes
were resolved on a 5% nondenaturing polyacrylamide (60:1
cross-link)-Tris-glycine gel, and autoradiographs were prepared by
exposure at
70°C using a Kodak X-OMAT film. To demonstrate
specificity of the protein-DNA complex, a 125 M excess of unlabeled
probe was added to the nuclear extract before adding the radiolabeled
probe. The sequence of the plus strand of the oligonucleotide was
5'-CAAACAGGGGGCTTTCCCTCCTC-3'.
Statistical analysis.
Data that are normally distributed are
expressed as mean values ± standard errors of the means (SEM).
For these data, an unpaired Student t test with Bonferroni
correction for multiple comparisons or analysis of variance (ANOVA)
with correction for multiple comparisons (Sheffe) was used for
statistical comparison of sample means as indicated in the figure
legends. Nonparametric analysis using the Wilcoxon rank test was
conducted on data that were not normally distributed. For these data,
the medians and ranges of the values are illustrated. A P
value of <0.05 was considered to be significant.
 |
RESULTS |
Initial deposition of B. cepacia in the lungs of
Cftr
/
and
Cftr+/+ mice.
To establish that
intranasal instillation efficiently delivered bacteria to the lungs of
experimental mice, 50 µl of PBS containing 107
CFU of B. cepacia isolate BC7 was instilled once
intranasally into three Cftr
/
and three
Cftr+/+ mice. Mice were sacrificed 2 h
later, and the lungs were harvested, homogenized, serially diluted, and
plated on B. cepacia isolation agar to determine the number
of viable bacteria. There was no observed difference between the three
Cftr
/
and the three
Cftr+/+ mice in the initial deposition
rate, which was consistently over 10% (i.e.,
>106 CFU/lung). Bacteria were detected by the
anti-B. cepacia antibody in all regions of the lungs (data
not shown). Control mice that were given only intranasal PBS
demonstrated no immunoreactivity with the anti-B. cepacia antibody.
Establishment of chronic pulmonary infection with B.
cepacia.
The next objective was to establish a more
chronic pulmonary infection with B. cepacia in mice with a
method that permitted physiologically relevant adhesive interactions
between the bacteria and respiratory epithelium without the need for
bacterial entrapment in agar beads. To accomplish this, sterile PBS or
B. cepacia (107 bacteria per mouse)
was administered on days 0, 3, 6, and 9 and the mice were sacrificed on
day 18. Two strains of B. cepacia, a clinical isolate from
the highly transmissible genomovar III, ET12 strain and an
environmental type strain isolated from onion rot (ATCC 25416;
genomovar I), were used to compare their virulence properties in mice.
Due to technical difficulties with the administration of the
anesthetic, 1 to 3 mice died in each group during the intranasal instillation procedure, and these mice were removed from the study leaving 9 Cftr+/+ and 10 Cftr
/
mice in group 1 (PBS), 10 Cftr+/+ and 16 Cftr
/
mice in group 2 (B. cepacia isolate BC7), and 3 Cftr+/+
and 4 Cftr
/
mice in group 3 (B. cepacia isolate ATCC 25416). Two of the 16 Cftr
/
mice in group 2, which were
infected with isolate BC7, died within a few hours after the fourth
instillation on day 9, and at necropsy the lungs from both of these
mice were characterized grossly by complete consolidation. The
bacterial loads in these two mice were 2.3 × 106 and 9.7 × 106
CFU/g of lungs at the time of death. All of the remaining mice were
sacrificed on day 18 and were used to generate data presented in this report.
The weights of the Cftr
/
mice
(mean = 15.3 ± 0.9 g) were slightly less than those of
Cftr+/+ controls (mean = 17.6 ± 0.8 g) at the beginning of the experiment. Both
Cftr
/
and
Cftr+/+ mice treated with PBS gained weight
(mean weight gains for Cftr
/
and
Cftr+/+ mice, 2.8 ± 0.2 and 3.1 ± 0.3 g, respectively). In contrast, Cftr
/
mice infected with isolate BC7
gained less weight during the experiment (1.6 ± 0.2 g) than
Cftr+/+ controls (2.9 ± 0.4 g).
Additionally, the Cftr
/
mice treated
with the BC7 strain appeared lethargic compared to wild-type controls.
Both the Cftr
/
and
Cftr+/+ mice infected with isolate ATCC
25416 gained weight (mean weight gains for
Cftr
/
and
Cftr+/+ mice, 2.7 ± 0.3 and 3.0 ± 0.4 g, respectively) and appeared well.
Persistence of viable B. cepacia in the lungs.
To determine the extent of bacterial persistence, lungs from each
animal were dissected under aseptic conditions, homogenized, and plated
on Burkholderia cepacia selective agar (BCSA) or
blood agar plates. The lungs of all
Cftr
/
animals that had received isolate
BC7 harbored from 1 × 104 to 5 × 105 (median of 5.3 × 104) CFU of viable bacteria/g of lungs. In
contrast, only three out of the eight
Cftr+/+ mice infected with B. cepacia isolate BC7 had viable bacteria in their lungs and the
counts were very low (<104 CFU/g). The other
five Cftr+/+ mice had no detectable
B. cepacia. By the Wilcoxon rank test, the difference
between mouse groups was statistically significant (P < 0.001). None of the mice infected with isolate ATCC 25416 yielded
positive lung cultures. Thus, even 9 days after the last exposure of
mice to bacteria, ET12 strain BC7 was more persistent than
environmental type strain ATCC 25416, and
Cftr
/
mice were more susceptible to
infection than Cftr+/+ mice. No viable
B. cepacia organisms were found in the spleen, blood, or BAL
fluid of either Cftr
/
or
Cftr+/+ mice infected with either BC7 or
ATCC 25416.
Instillation of B. cepacia results in
bronchopneumonia.
On visual inspection, the lungs of both
Cftr+/+ and
Cftr
/
mice treated with PBS alone or
B. cepacia ATCC 25416 were grossly normal. Lungs of
Cftr+/+ mice infected with BC7 appeared
healthy, with only occasional areas of atelectasis. In contrast, the
lungs from Cftr
/
mice infected with BC7
were found to be friable and showed diffuse areas of consolidation and
atelectasis. The lungs of both Cftr
/
and Cftr+/+ mice infected with ATCC 25416 demonstrated minimal evidence of pathology.
By histological examination,
Cftr+/+ mice
given PBS alone showed no evidence of inflammation of airway or lung
parenchyma (Fig.
1a). Bronchi and
bronchioles were lined by a constitutively normal
population of
ciliated and nonciliated (Clara) columnar epithelial
cells with
randomly distributed PAS-positive mucus-secreting cells
(Fig.
1b). Mice
of genotype
Cftr
/
treated with PBS (not
presented) also exhibited mostly normal
lungs, although a few small,
scattered areas of peribronchiolar
and perivascular mononuclear cell
cuffing were noted. Occasionally
there were also small random
multifocal patches of interstitial
thickening characterized by
fibroblast hypertrophy and mono- and
polymorphonuclear inflammatory
cell infiltration (data not shown).
Thus lungs from
Cftr
/
mice contained minor inflammatory
changes in the absence of infection,
presumably due to the effects of
repeated instillation of PBS
. Cftr+/+ mice
infected with isolate BC7 or ATCC 25416 were similar to
each other in
showing mostly normal and functional lungs, as seen
in control,
PBS-treated mice. However, in a few scattered areas
there was
peribronchiolar and perivascular inflammation (Fig.
1c). The epithelia
of bronchioles were normal, but there were
occasional small areas of
hypertrophy of resident interstitial
cells with associated infiltration
by mononuclear inflammatory
cells, consistent with pneumonitis (Fig.
1d). Therefore both BC7
and ATCC 25416 appeared to have caused a mild
inflammatory response
in
Cftr+/+ mice.

View larger version (100K):
[in this window]
[in a new window]
|
FIG. 1.
Lung histology of Cftr+/+
mice after repeated exposure to PBS or B. cepacia
isolate BC7. (a, c, and d) Hematoxylin- and eosin-stained sections; (b)
PAS/Alcian blue-stained section. Representative sections of
Cftr+/+ mice treated with PBS showing normal
lung histology (a) with few PAS-positive goblet cells in the
bronchiolar epithelia (b). Cftr+/+ mice
exposed to BC7 demonstrated occasional perivascular and peribronchiolar
inflammation (c) and small areas with mild hypertrophy of resident
interstitial cells (d).
|
|
The histological appearance of the lungs of
Cftr
/
mice treated with isolate BC7 was
considerably different. There were almost
no normal areas of lung
remaining, and in many regions there was
complete pneumonic
consolidation (Fig.
2a).
Moderate-to-severe
infiltration by lymphoplasmacytic cells was observed
in most of
the peribronchiolar and perivascular spaces. Epithelia of
the
affected airways exhibited striking Clara cell hyperplasia,
prominent
PAS-reactive domed apical hypersecretion, and mucus-like
material
over the luminal surface (Fig.
2b and c). The majority of the
parenchyma was characterized by moderate-to-severe infiltration
of
alveolar septa by a mixed population of inflammatory cells
composed
predominantly of macrophages with some neutrophils (Fig.
2d). The
airspace epithelium showed marked hypertrophy of type
II pneumocytes
and exudation by foamy vacuolated macrophages (Fig.
2e). None of the
sections showed evidence of fibrosis. In contrast,
Cftr
/
mice infected with isolate ATCC
25416 did not show any marked
pathological changes and resembled
Cftr+/+ mice infected with the same isolate
(not illustrated). Therefore
clinical isolate BC7, but not isolate ATCC
25416, elicited a severe
inflammatory response only in
Cftr
/
mice. These observations may
reflect differences between strains
or the importance of bacterial
virulence factors.

View larger version (109K):
[in this window]
[in a new window]
|
FIG. 2.
Representative lung sections of
Cftr / mice after repeated exposure to
B. cepacia isolate BC7. (a, c, d) Hematoxylin- and
eosin-stained sections; (b) PAS/Alcian blue-stained section; (e)
section stained with Giemsa. The histological sections demonstrate
hypertrophy of PAS-positive cells in bronchiolar epithelia, hypertrophy
of Clara cells, mucus retention in airways, inflamed parenchyma
characterized by marked hypertrophy of resident interstitial cells with
infiltration by macrophages and neutrophils, and consolidation of
alveolar airspaces by an exudation of inflammatory cells and debris.
|
|
To quantify these changes, the lung sections were examined by a
veterinary pathologist who was blinded to the genotype of
the mice and
the treatment given. Severity scores for each mouse
are given in Table
1. ATCC 25416-infected
Cftr+/+ and
Cftr
/
mice and BC7-infected
Cftr+/+ mice showed very-mild-to-moderate
inflammation in the lungs,
with the score ranging from 1 to 3.
Cftr
/
mice infected with isolate BC7
showed moderate-to-severe bronchiolitis
and pneumonia, with the score
consistently averaging between 4
and 5. Thus the ET12 strain (isolate
BC7), in addition to its
greater pulmonary persistence 9 days after the
last nasal instillation,
also caused much more severe inflammation than
did the environmental
type strain (ATCC 25416).
Localization of B. cepacia in the lungs.
To
determine the anatomical site of the persistent bacteria, the lungs
were examined by immunofluorescence microscopy using an antibody
specific for B. cepacia. For both genotypes, mice that were
infected with isolate ATCC 25416 harbored no bacteria in their lungs,
despite evidence of mild inflammation. In contrast, BC7-infected
Cftr
/
mice demonstrated bacteria in the
consolidated and inflamed peribronchiolar and perivascular areas (Fig.
3a and b) and in the thickened alveolar septa and in areas of consolidation (Fig. 3e and f).
Cftr+/+ mice also showed bacteria in
inflamed peribronchiolar areas (Fig. 3c and d) and thickened alveolar
septa (Fig. 3g and h), but the density was much lower that for that for
Cftr
/
mice.

View larger version (129K):
[in this window]
[in a new window]
|
FIG. 3.
Immunolocalization of B. cepacia in the
lungs of Cftr+/+ and
Cftr / mice infected with isolate BC7.
Paraffin sections (5 µm thick) were deparaffinized, rehydrated,
heated in 10 mM sodium citrate buffer, pH 6.0, blocked with 5% normal
donkey serum, and incubated overnight at 4°C with anti-B.
cepacia antibody (diluted 1:1,000), and the bound
antibody was detected by CY-3-conjugated anti-rabbit immunoglobulin G. (b and d) Bacteria in inflamed bronchoalveolar areas of
Cftr / and
Cftr+/+ mouse lungs, respectively; (f and h)
bacteria in infiltrated and inflamed parenchyma of
Cftr / and
Cftr+/+ mouse lungs, respectively; (a, c, e,
and g) hematoxylin- and eosin-stained sections corresponding to panels
b, d, f, and h, respectively.
|
|
Characteristics of BAL fluid cell populations.
The cellular
characteristics of BAL fluid were examined 9 days after the final
instillation of bacteria. The total number of cells present in BAL
fluid was significantly greater for
Cftr
/
than for
Cftr+/+ mice treated with isolate BC7, and
numbers for both mouse types were greater than those for the
corresponding mice treated with PBS or isolate ATCC 25416 (Fig.
4a). In mice treated with PBS, macrophages comprised the majority of alveolar cells in both
Cftr
/
and
Cftr+/+ mice (Fig. 4b). However, there was
a significantly higher proportion of neutrophils (31.8%) in
Cftr
/
mice than in
Cftr+/+ mice (14.1%; P < 0.02) infected with isolate BC7. The neutrophilia, as assessed by
Wright-Giemsa staining of cytospins, corresponded to an increase
in surface expression of myeloid differentiation antigen Ly-6G (GR-1)
(13) in BAL cells as determined by flow cytometry (Fig.
4c).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 4.
(a and b) Total and differential cell counts in BAL
fluid from Cftr+/+ and
Cftr / mice treated with PBS or B.
cepacia (either BC7 or ATCC 25416). BAL fluid was harvested
from each mouse by washing with three 1-ml aliquots of PBS via a
cannulated trachea. Cells from 100 µl of BAL fluid were
cytocentrifuged onto a slide, fixed with methanol, and stained with a
modified Wright-Giemsa stain. Total numbers of cells and
different cell types were determined by counting a minimum of 300 cells/slide. (a) Total numbers of cells; (b) differential cell counts.
Bars, cell averages from two (ATCC 25416) and seven (PBS and BC7)
animals in each group. SEM were calculated only for groups that had
more than four animals. Asterisk, statistically significant difference
between the groups as determined by ANOVA with correction for multiple
comparisons (Sheffe). (c) Surface expression of myeloid marker Ly-6G
(Gr-1) on cells recovered in BAL fluid from
Cftr+/+ and
Cftr / mice treated with PBS or B.
cepacia isolate BC7. Analysis was done by flow cytometry as
outlined in Materials and Methods. Asterisk, statistically significant
differences between the groups as determined by ANOVA with correction
for multiple comparisons (Sheffe). (d and e) Assessment of neutrophil
activation in cells recovered by BAL. Shown is oxidant production, as
indicated by surface expression of 2 integrin CD11b (d)
and oxidation of dihydrorhodamine (e) and by neutrophils recovered by
BAL from Cftr+/+ and
Cftr / mice treated with PBS or B.
cepacia isolate BC7. Analysis was done by flow cytometry as
outlined in Materials and Methods. Asterisk, statistically significant
differences between the groups as determined by ANOVA with correction
for multiple comparisons (Sheffe).
|
|
Despite the increased percentage of neutrophils in BAL fluid of
Cftr
/
mice, there was no significant
difference in the degree of neutrophil
activation between
Cftr
/
and
Cftr+/+ mice infected with
B. cepacia, as assessed by determining surface
expression of

2
integrin CD11b/CD18 (Fig.
4d) or oxidant production
(Fig.
4e).
Importantly, these cells were capable of activation
when removed from
the milieu of the
Cftr
/
lung, because
exposure of the neutrophils recovered by lavage
to
phorbol-12-myristate-13-acetate, a potent neutrophil-activating
agent,
resulted in increased oxidant production (Fig.
4e). Thus,
despite the
presence of increased numbers of viable bacteria in
the lungs and
increased numbers of neutrophils in the BAL fluid
of
Cftr
/
mice, there was no evidence of
enhanced neutrophil activation
in the lung, which might be anticipated
under these
circumstances.
Analysis of the cells recovered in BAL fluid also revealed an increased
proportion of lymphocytes from both
Cftr+/+
and
Cftr
/
mice treated with BC7 (Fig.
4b). Further analysis of lymphocyte
subtypes demonstrated that the
majority (>80%) of these cells
were neither T nor B
cells.
Association of B. cepacia with the cells of BAL
fluid.
In the cells recovered by BAL lavage from
Cftr+/+ mice infected with isolate BC7, a
significant number of macrophages were associated with immunoreactive
B. cepacia (Fig. 5a). In
contrast, in comparable Cftr
/
mice,
there were relatively fewer macrophages associated with bacteria (Fig.
5b), suggesting that alveolar macrophages from Cftr+/+ mice may be more efficient in
phagocytosing bacteria than those from
Cftr
/
mice.

View larger version (52K):
[in this window]
[in a new window]
|
FIG. 5.
Association of B. cepacia with alveolar
macrophages in Cftr+/+ and
Cftr / mice infected with BC7. Cells from
100 µl of BAL fluid were cytocentrifuged onto a slide, fixed in cold
methanol, blocked with 5% normal donkey serum, and treated with
anti-B. cepacia antibody as described for Fig. 4. Shown
is the association of bacteria with alveolar macrophages harvested from
the lungs of Cftr+/+ (a) and
Cftr / (b) mice.
|
|
Assessment of macrophage activation.
To assess the extent of
macrophage activation, the levels of surface expression of F4/80 and
MHC-II molecules (markers of macrophage activation) were determined by
flow cytometry. CD11c expression was also measured as a marker for the
total macrophage population. PBS control and BC7-infected
Cftr
/
and
Cftr+/+ mice did not differ in their levels
of CD11c surface expression (data not shown). A minor percentage
(<15%) of macrophages from all groups expressed F4/80, and no
significant differences between Cftr
/
and Cftr+/+ mice infected with isolate BC7
were noted (data not shown). In contrast, macrophages from BC7-infected
Cftr+/+ mice expressed 3.5 times more
MHC-II than macrophages from similarly treated
Cftr
/
mice (Fig.
6). These results indicate that, despite
an enhanced pulmonary bacterial load, the alveolar macrophages
recovered from Cftr
/
mice demonstrated
suboptimal activation compared with those from Cftr+/+ mice.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 6.
Surface expression of MHC-II molecules on alveolar
macrophages recovered by BAL. Cells from 100 µl of BAL fluid were
incubated with 20% FBS for 30 min, washed with 10% FBS, and incubated
with fluorescein isothiocyanate-conjugated anti-CD11c (not shown) and
phycoerythrin-conjugated anti-MHC-II. Cells were washed to remove
excess antibodies and fixed with 1.6% paraformaldehyde, and
fluorescence was quantified by flow cytometry. Macrophages were gated
by a combination of light scattering and CD11c staining. The level of
MHC-II expression was assessed on the gated cells. Asterisk,
statistically significant difference between the groups, as determined
by ANOVA with correction for multiple comparisons (Sheffe).
|
|
Transcription factor activation.
The transcription of many
genes involved in acute inflammation (e.g., interleukin-1 [IL-1] and
IL-6, TNF-
, and intercellular adhesion molecule 1 genes) is
regulated by transcription factors such as CREB and NF-
B (5,
27). To determine if the observed differences in the
inflammatory response could be accounted for by variations in this
aspect of inflammatory gene regulation, the nuclear translocation of
these factors was determined in whole-lung extracts using EMSA. Low
levels of nuclear translocation of CREB were present in all groups and
did not differ between Cftr+/+ and
Cftr
/
mice (data not shown). The
pattern of NF-
B translocation was more complex (Fig.
7). In all
Cftr+/+ mice treated with isolate BC7,
increased levels of nuclear NF-
B were present compared with those in
PBS controls. In five of seven Cftr
/
mice, the levels of nuclear NF-
B were very low, while in two Cftr
/
mice high levels of NF-
B,
similar to those in wild-type mice, were present.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 7.
Nuclear translocation of NF- B. Nuclear levels of
transcription factor NF- B were measured by EMSA as described in
Materials and Methods. (a) Representative autoradiogram of EMSA
illustrating specific NF- B binding activity. Lanes 1 and 2, Cftr+/+ and
Cftr / mice, respectively, treated with
PBS; lanes 3 and 4, Cftr+/+ and
Cftr / mice, respectively, treated with
BC7; lane 5, control with an excess of cold oligonucleotides to
demonstrate specificity of the probe; lane 6, positive control. (b)
Histogram summarizing the results of seven or eight experiments with
nuclear extracts from lungs from Cftr+/+ and
Cftr / mice treated with PBS or B.
cepacia isolate BC7.
|
|
Lung cytokine levels.
The levels of selected cytokines
(TNF-
, IFN-
, MIP-2, and KC) in BAL fluid were measured by
ELISA (Table 2). The levels of TNF-
and IFN-
were variable and did not differ significantly between the
groups. The levels of KC and MIP-2 were elevated in both
Cftr+/+ and
Cftr
/
mice infected with isolate BC7
compared with those in PBS-treated controls. Notably, the levels of the
CXC chemokine KC were elevated greater than twofold in
Cftr
/
mice compared to those in
Cftr+/+ mice infected with BC7
(P = 0.02 by t test). The elevation in the
level of KC in Cftr
/
mice is consistent
with the neutrophil predominance in BAL fluid (Fig. 4b).
 |
DISCUSSION |
In the present study, we have demonstrated that a clinical isolate
of B. cepacia, BC7, belonging to the highly transmissible genomovar III, ET12 strain (28, 59), from a case of CF
persisted preferentially in the lungs of mice with CF 9 days after the
last instillation without the use of bacterium-immobilizing
agents. The Cftr
/
mice
demonstrated an enhanced pulmonary inflammatory response but one that
was apparently less effective than that for
Cftr+/+ mice. On the other hand, an
environmental type strain of B. cepacia (isolate ATCC
25416), which is predominantly a plant pathogen, did not persist or
cause excessive inflammation in either
Cftr
/
or
Cftr+/+ mice. Taken together, these
observations suggest that the absence of functional CFTR in the lung
creates a milieu that interferes with macrophage and neutrophil
function and thereby impedes the clearance of a clinically relevant
strain of B. cepacia from the lung. Additionally, the
predilection for enhanced pulmonary inflammation and injury was
dependent in part on bacterial virulence. It is noteworthy that only
two Cftr
/
mice died of lung infection,
indicating that, similar to the human CF patient population, few mice
with CF succumb to the initial stages of the infection. Rather, most
mice with CF develop a more persistent infection that promotes an
excessive and prolonged inflammatory response leading to progressive
lung injury, as indicated by the pathological changes observed in
infected Cftr
/
mice.
There was a significantly increased proportion of neutrophils present
within the airspace of Cftr
/
mice
infected with B. cepacia isolate BC7. The mechanism of this enhanced neutrophil infiltration and accumulation could involve enhanced recruitment, diminished clearance, or a combination thereof. Enhanced neutrophil recruitment could be due to the increased numbers
of bacteria remaining in the lungs of mice with CF, which would promote
the release of chemoattractant molecules such as the CXC chemokine KC
from pulmonary macrophages, lymphocytes, and epithelial cells. However,
it is also possible that intrinsic differences in the lungs of mice
with CF predispose them to the increased recruitment and/or the
decreased clearance of neutrophils. Several hypotheses have been
proposed to account for the enhanced predilection of lungs of animals
with CF for infection and excessive inflammation including (i)
increased airway surface liquid absorption leading to depletion of the
periciliary liquid layer and diminished mucociliary clearance
(34), (ii) failure of airway epithelial cells in animals
with CF to ingest bacteria and be sloughed, resulting in enhanced
bacterial retention (40), (iii) abnormal surface properties of airway epithelial cells in animals with CF, leading to
enhanced mucus secretion, adherence, and retention of bacteria in the
lung (42), and (iv) leukocytes that fail to ingest and/or kill bacteria in the milieu of the epithelial lining fluid of animals
with CF.
Although the present study did not address these mechanisms directly,
our observations suggest that a contributing factor is defective
activation and microbicidal function of pulmonary neutrophils and
macrophages. Moreover, our model reflects the clinical situation where
increased neutrophils are commonly seen in CF patients in association
with chronic infection and advanced lung injury (25, 26).
Despite their abundance in the lungs of animals with CF, the
intrapulmonary neutrophils are apparently less effective at reducing
the bacterial burden in CF. Moreover, despite the presence of viable
bacteria in the lungs of animals with CF, minimal evidence of enhanced
activation, as assessed by oxidant production and surface expression of
CD11b, was observed in the Cftr
/
mice.
In this regard, it is noteworthy that in vitro exposure of neutrophils
to lipopolysaccharide (LPS) from an ET12 strain of B. cepacia (isolate J2315, genomovar III) results in cell activation including NADPH oxidase activity and enhanced surface expression of
CD11b (21). One possible explanation for these apparently discrepant observations is that live bacteria (as opposed to purified LPS) release toxins that prevent optimal neutrophil activation. Additionally, it is possible that factors present in the milieu of the
lungs of animals with CF prevent complete activation of neutrophils.
Because we studied these facets of neutrophil function at only a single
time point (9 days) after the establishment of infection, a more
comprehensive examination of neutrophil activation is now required.
Macrophages are also important effectors of lung defense as they are
both bactericidal and have critical immune system-activating functions, including antigen presentation and orchestration of the pulmonary immune response by virtue of cytokine and chemokine production (65). We observed that, despite a much larger
bacterial burden in the lungs of Cftr
/
mice, the levels of MHC-II surface expression, an indicator of macrophage activation, were much lower in these mice than in their wild-type counterparts. There are at least two possible explanations for these observations. One is that specific (but as yet
uncharacterized) virulence factors of B. cepacia directly
limit MHC expression and other aspects of macrophage activation as a
means of evading the innate immune system. Similar evasion of host
defenses has been demonstrated for other respiratory pathogens
(36). A second possibility is that the unique milieu of
the lungs of animals with CF may impede macrophage activation and
microbicidal activity.
The localization of B. cepacia in the lungs of
Cftr
/
mice to the alveolar septum in
our studies is noteworthy and is in contrast to the usual situation in
human CF patients, where chronic airway infection predominates
(11). However, the localization of B. cepacia
to the alveolar septum in human CF patients has recently been reported
(44) and may reflect evasion by the virulent bacteria of
host defense systems, allowing movement of the bacteria across the
epithelial barrier and into the interstitial space. This translocation may presage the development of pneumonia and eventually systemic dissemination with the development of cepacia syndrome, a devastating condition associated with a high mortality (12, 60).
Animal models for CF have proven to be useful in studying the
physiological significance of mutations in the Cftr locus
that predispose animals to chronic lung infections and subsequent
inflammatory lung injury. To date, various models have shown a
predilection of the lungs of mice with CF for infection with several
opportunistic pathogens including P. aeruginosa,
Haemophilus influenzae, S. aureus, and B. cepacia (10, 14, 19). However, to establish bacterial
infection in rodent lungs, some investigators have used immobilizing
agents such as agar beads (14, 19) which bypass colonization mechanisms such as interactions between bacterial adhesins
and respiratory epithelial cells (42, 46, 47, 49, 50).
Most studies to date have focused on the host response to infection
with P. aeruginosa and S. aureus, while
information regarding the host response to B. cepacia is
more limited, in part because of the difficulties of establishing a
pulmonary infection with this organism. One study, however, compared
the acute responses to challenge with aerosolized B. cepacia
or S. aureus, without the use of agar beads, in
Cftr+/+ and
Cftr
/
mice (10). These
Cftr
/
mice, generated by targeted
insertional mutagenesis of exon 10 (Cftrm1HGU), were repeatedly exposed to
aerosolized S. aureus and B. cepacia in separate
experiments. It is notable that the B. cepacia used in this
study (J2315; genomovar III) was also an ET12 strain. Bacterial
clearance was significantly impaired, and the histopathological abnormalities were more pronounced for both organisms in CFTR-deficient mice than in wild-type controls. Mice infected with S. aureus demonstrated bronchitis and bronchiolitis, whereas those
infected with B. cepacia demonstrated severe
bronchopneumonia. The pathological changes seen with B. cepacia are similar but more severe than those seen in our model.
To achieve these results, the experimental protocol involved
aerosolization of bacteria daily for an entire month. This represents a
much greater bacterial load than that used in our study.
In contrast, when another strain of CFTR-deficient mice
(Cftrm1UNC; S489X null mutant) was
challenged with S. aureus, no differences in bacterial
clearance between CFTR-deficient mice and the controls were
demonstrated (55). In this study, no mechanical
immobilizing agents were used to increase retention of the bacteria in
the lungs. However, when these same
Cftrm1UNC mice were given P. aeruginosa enmeshed in agar beads (19), an increased
mortality and elevated levels of inflammatory cytokines (TNF-
,
MIP-2, and KC) were noted early in the course of infection in mice with
CF compared to controls. No differences in either bacterial burden or
in the composition of inflammatory cells in BAL were noted, however,
between mice with CF and wild-type control mice. In our study,
pathological changes were much more severe in the
Cftr
/
mice than in the
Cftr+/+ mice treated with B. cepacia, a difference that may reflect the repetitive-exposure
regimen using intranasal instillation.
In our model, no viable B. cepacia organisms were found in
the spleens or blood of either Cftr
/
or
Cftr+/+ mice infected with either B. cepacia clinical isolate BC7 (ET12 strain) or the environmental
type strain (isolate ATCC 25416). This lack of systemic dissemination
is in contrast to the report by Speert and colleagues, who infected
IFN-
knockout mice with B. multivorans (genomovar II)
isolated from a patient with chronic granulomatous disease and
recovered viable bacteria from the spleen (58). This
discrepancy may reflect variations in the route of administration of
the bacteria (intranasal versus intraperitoneal), differences in the
pathogenicities of the two strains of B. cepacia (ET12
strain of genomovar III versus B. multivorans) used, or the
generalized compromise of the immune system in the IFN-
knockout mice compared to the apparently localized compromise of pulmonary host
defenses in the CF knockout mice.
It is not clear why CF predisposes patients to acquisition of B. cepacia. Host lung factors undoubtedly play an important role, and
B. cepacia infections usually occur in patients with lung
damage due to chronic infection by P. aeruginosa (16,
30). Indeed, human CF patients are frequently infected by
several different bacteria, and this polymicrobial infection may alter
the host response to B. cepacia (21). In our
murine studies, we did not attempt to model this more-complex
situation. Another factor to be considered in humans is one of repeated
exposure to B. cepacia. Epidemic-like spread of B. cepacia usually occurs in a pattern reflecting close
person-to-person social contacts, suggesting that recurrent exposure to
the pathogen is important in increasing susceptibility to infection
(15, 28, 37, 53). Our murine system with repetitive
exposure to B. cepacia was designed to model this
environment. It should be noted that even apparently immunocompetent
patients can develop B. cepacia pneumonia if host defenses
are overwhelmed (1, 29, 64).
Specific bacterial factors are also assumed to play an important role
in determining the clinical severity of B. cepacia
infections in CF patients. Bacterial virulence factors that have been
proposed include surface cable pili, which are expressed by some
B. cepacia isolates of the ET12 strain and which mediate
adherence to mucins and epithelial cells (46, 47, 49, 50),
extracellular proteases (57), lipases (31),
siderophores (9), hemolysins (22), LPS
(21, 66), and melanin-like pigment (67). The
ability of some strains of B. cepacia to enter epithelial
cells and macrophages and to replicate intracellularly (3, 33,
43) and their resistance to phagocytic killing (67)
are also likely to contribute to virulence.
Infection with B. cepacia remains an important clinical
problem for CF patients in many centers, yet this pathogen and the host
response to this infection remain poorly understood. In this study, we
have reported the development and characterization of a murine model of
chronic pneumonia due to B. cepacia that leads to bacterial
persistence and chronic pulmonary inflammation consistent with clinical
CF disease. Importantly, we provide evidence that there is suboptimal
activation of pulmonary neutrophils and macrophages in the milieu of
the lungs of animals with CF that may contribute to bacterial
persistence. Further studies using this model will allow a better
understanding of the host-microbe interaction for B. cepacia
and the ineffective, yet exaggerated, inflammatory response that
characterizes this disease. Given the lack of adequate therapy for
treating B. cepacia infection, this model may also allow for
the development and testing of novel therapies to limit bacterial and
immune-system-mediated lung damage.
 |
ACKNOWLEDGMENTS |
This work was supported by operating grants from the National
Institutes of Health (P50 DK49096-06 SCORE) to G. P. Downey and
the Canadian Cystic Fibrosis Foundation to J. Forstner. G. P. Downey is the R. Fraser Elliott Chair in Transplantation Research for
the Toronto General Hospital of the University Health Network and is
the recipient of a Canada Research Chair in respiration from the
Canadian Institutes of Health Research.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Clinical
Sciences Division, Rm. 6264 Medical Sciences Building, University of
Toronto, 1 Kings College Circle, Toronto, Ontario, Canada M5S 1A8.
Phone: (416) 978-8923. Fax: (416) 971-2112. E-mail:
gregory.downey{at}utoronto.ca.
Editor:
E. I. Tuomanen
 |
REFERENCES |
| 1.
|
Belchis, D. A.,
E. Simpson, and T. Colby.
2000.
Histopathologic features of Burkholderia cepacia pneumonia in patients without cystic fibrosis.
Mod. Pathol.
13:369-372[CrossRef][Medline].
|
| 2.
|
Brisse, S.,
C. M. Verduin,
D. Milatovic,
A. Fluit,
J. Verhoef,
S. Laevens,
P. Vandamme,
B. Tummler,
H. A. Verbrugh, and A. van Belkum.
2000.
Distinguishing species of the Burkholderia cepacia complex and Burkholderia gladioli by automated ribotyping.
J. Clin. Microbiol.
38:1876-1884[Abstract/Free Full Text].
|
| 3.
|
Burns, J. L.,
M. Jonas,
E. Y. Chil,
D. K. Clark,
A. Berger, and A. Griffith.
1996.
Invasion of respiratory epithelial cells by Burkholderia (Pseudomonas) cepacia.
Infect. Immun.
64:4054-4059[Abstract].
|
| 4.
|
Cantin, A.
1995.
Cystic fibrosis lung inflammation: early, sustained, and severe.
Am. J. Respir. Crit. Care Med.
151:939-941[Medline].
|
| 5.
|
Chandra, G.,
J. P. Cogswell,
L. R. Miller,
M. M. Godlevski,
S. W. Stinnett,
S. L. Noel,
S. H. Kadwell,
T. A. Kost, and J. G. Gray.
1995.
Cyclic AMP signaling pathways are important in IL-1 beta transcriptional regulation.
J. Immunol.
155:4535-4543[Abstract].
|
| 6.
|
Cheng, P. W.,
T. F. Boat,
K. Cranfill,
J. R. Yankaskas, and R. C. Boucher.
1989.
Increased sulfation of glycoconjugates by cultured nasal epithelial cells from patients with cystic fibrosis.
J. Clin. Investig.
84:68-72.
|
| 7.
|
Chroneos, Z. C.,
S. E. Wert,
J. E. Livingston,
D. J. Hassett, and J. A. Whitsett.
2000.
Role of cystic fibrosis transmembrane conductance regulator in pulmonary clearance of Pseudomonas aeruginosa in vivo.
J. Immunol.
165:3941-3950[Abstract/Free Full Text].
|
| 8.
|
Cressman, V. L.,
E. M. Hicks,
W. K. Funkhouser,
D. C. Backlund, and B. H. Koller.
1998.
The relationship of chronic mucin secretion to airway disease in normal and CFTR-deficient mice.
Am. J. Respir. Cell Mol. Biol.
19:853-866[Abstract/Free Full Text].
|
| 9.
|
Darling, P.,
M. Chan,
A. D. Cox, and P. A. Sokol.
1998.
Siderophore production by cystic fibrosis isolates of Burkholderia cepacia.
Infect. Immun.
66:874-877[Abstract/Free Full Text].
|
| 10.
|
Davidson, D. J.,
J. R. Dorin,
G. McLachlan,
V. Ranaldi,
D. Lamb,
C. Doherty,
J. Govan, and D. J. Porteous.
1995.
Lung disease in the cystic fibrosis mouse exposed to bacterial pathogens.
Nat. Genet.
9:351-357[CrossRef][Medline].
|
| 11.
|
Davis, P. B. (ed.).
1993.
Pathophysiology of the lung disease in cystic fibrosis.
Marcel Dekker, New York, N.Y.
|
| 12.
|
Dobbin, C. J.,
R. Soni,
T. Jelihovsky, and P. T. P. Bye.
2000.
Cepacia syndrome occurring following prolonged colonization with Burkholderia cepacia.
Aust. N. Z. J. Med.
30:288-289[Medline].
|
| 13.
|
Fleming, T. J.,
M. L. Fleming, and T. R. Malek.
1993.
Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family.
J. Immunol.
151:2399-2408[Abstract].
|
| 14.
|
Gossellin, D.,
M. M. Stevenson,
E. A. Cowley,
U. Griesenbach,
D. H. Eidelman,
M. Boule,
M. Tam,
G. Kent,
E. Skamene,
L. Tsui, and D. Radzioch.
1998.
Impaired ability of Cftr knockout mice to control lung infection with Pseudomonas aeruginosa.
Am. J. Respir. Crit. Care Med.
157:1253-1262[Abstract/Free Full Text].
|
| 15.
|
Govan, J. R.,
P. H. Brown,
J. Maddison,
C. J. Doherty,
J. W. Nelson,
M. Dodd,
A. P. Greening, and A. K. Webb.
1993.
Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis.
Lancet
342:15-19[CrossRef][Medline].
|
| 16.
|
Govan, J. R., and V. Deretic.
1996.
Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.
Microbiol. Rev.
60:539-574[Abstract/Free Full Text].
|
| 17.
|
Govan, J. R.,
J. E. Hughes, and P. Vandamme.
1996.
Burkholderia cepacia: medical, taxonomic and ecological issues.
J. Med. Microbiol.
45:395-407[Abstract/Free Full Text].
|
| 18.
|
Guggino, W. B.
1999.
Cystic fibrosis and the salt controversy.
Cell
96:607-610[CrossRef][Medline].
|
| 19.
|
Heeckeren, A. N.,
R. Walenga,
M. W. Konstan,
T. Bonfield,
P. B. Davis, and T. Ferkol.
1997.
Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa.
J. Clin. Investig.
100:2810-2815[Medline].
|
| 20.
|
Henry, D. A.,
M. E. Campbell,
J. J. LiPuma, and D. P. Speert.
1997.
Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium.
J. Clin. Microbiol.
35:614-619[Abstract].
|
| 21.
|
Hughes, J. E.,
J. Stewart,
G. R. Barclay, and J. R. Govan.
1997.
Priming of neutrophil respiratory burst activity by lipopolysaccharide from Burkholderia cepacia.
Infect. Immun.
65:4281-4287[Abstract].
|
| 22.
|
Hutchison, M. L.,
I. R. Poxton, and J. R. Govan.
1998.
Burkholderia cepacia produces a hemolysin that is capable of inducing apoptosis and degranulation of mammalian phagocytes.
Infect. Immun.
66:2033-2039[Abstract/Free Full Text].
|
| 23.
|
Isles, A.,
I. Maclusky,
M. Corey,
R. Gold,
C. Prober,
P. Fleming, and H. Levison.
1984.
Pseudomonas cepacia infection in cystic fibrosis: an emerging problem.
J. Pediatr.
104:206-210[Medline].
|
| 24.
|
Kent, G.,
M. Oliver,
J. K. Foskett,
H. Frndova,
P. Durie,
J. Forstner,
G. G. Forstner,
J. R. Riordan,
D. Percy, and M. Buchwald.
1996.
Phenotypic abnormalities in long-term surviving cystic fibrosis mice.
Pediatr. Res.
40:233-241[Medline].
|
| 25.
|
Khan, T. Z.,
J. S. Wagnener,
T. Bost,
J. Martinez,
J. Accurso, and D. W. H. Riches.
1995.
Early pulmonary inflammation in infants with cystic fibrosis.
Am. J. Respir. Crit. Care Med.
151:1075-1082[Abstract].
|
| 26.
|
Konstan, M. W.
1996.
Treatment of airway inflammation in cystic fibrosis.
Curr. Opin. Pulm. Med.
2:452-456[Medline].
|
| 27.
|
Ledebur, H. C., and T. P. Parks.
1995.
Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. Essential roles of a variant NF-kappa B site and p65 homodimers.
J. Biol. Chem.
270:933-943[Abstract/Free Full Text].
|
| 28.
|
Ledson, M. J.,
M. J. Gallagher,
J. E. Corkill,
C. A. Hart, and M. J. Walshaw.
1998.
Cross infection between cystic fibrosis patients colonised with Burkholderia cepacia.
Thorax
53:432-436[Abstract/Free Full Text].
|
| 29.
|
Ledson, M. J.,
M. J. Gallagher, and M. J. Walshaw.
1998.
Chronic Burkholderia cepacia bronchiectasis in a noncystic fibrosis individual.
Thorax
53:430-432[Abstract/Free Full Text].
|
| 30.
|
LiPuma, J. J.
1998.
Burkholderia cepacia. Management issues and new insights.
Clin. Chest Med.
19:473-486[CrossRef][Medline].
|
| 31.
|
Lonon, M. K.,
D. E. Woods, and D. C. Straus.
1988.
Production of lipase by clinical isolates of Pseudomonas cepacia.
J. Clin. Microbiol.
26:979-984[Abstract/Free Full Text].
|
| 32.
|
Mahenthiralingam, E.,
T. Coenye,
J. W. Chung,
D. P. Speert,
J. R. Govan,
P. Taylor, and P. Vandamme.
2000.
Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex.
J. Clin. Microbiol.
38:910-913[Abstract/Free Full Text].
|
| 33.
|
Martin, D. W., and C. D. Mohr.
2000.
Invasion and intracellular survival of Burkholderia cepacia.
Infect. Immun.
68:24-29[Abstract/Free Full Text].
|
| 34.
|
Matsui, H.,
B. R. Grubb,
R. Tarran,
S. H. Randell,
J. T. Gatzy,
C. W. Davis, and R. C. Boucher.
1998.
Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease.
Cell
95:1005-1015[CrossRef][Medline].
|
| 35.
|
McCray, P. B., Jr.,
J. Zabner,
H. P. Jia,
M. J. Welsh, and P. S. Thorne.
1999.
Efficient killing of inhaled bacteria in DeltaF508 mice: role of airway surface liquid composition.
Am. J. Physiol.
277:L183-L190[Abstract/Free Full Text].
|
| 36.
|
McGuirk, P., and K. H. Mills.
2000.
Direct anti-inflammatory effect of a bacterial virulence factor: IL-10-dependent suppression of IL-12 production by filamentous hemagglutinin from Bordetella pertussis.
Eur. J. Immunol.
30:415-422[CrossRef][Medline].
|
| 37.
|
Muhdi, K.,
F. P. Edenborough,
L. Gumery,
S. O'Hickey,
E. G. Smith,
D. L. Smith, and D. E. Stableforth.
1996.
Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic.
Thorax
51:374-377[Abstract/Free Full Text].
|
| 38.
|
Nathens, A. B.,
R. Bitar,
C. Davreux,
M. Bujard,
J. C. Marshall,
A. P. Dackiw,
R. W. Watson, and O. D. Rotstein.
1997.
Pyrrolidine dithiocarbamate attenuates endotoxin-induced acute lung injury.
Am. J. Respir. Cell Mol. Biol.
17:608-616[Abstract/Free Full Text].
|
| 39.
|
Nelson, J. W.,
S. L. Butler,
D. Krief, and R. W. Govan.
1944.
Virulence factors of Burkholderia cepacia.
FEMS Immunol. Med. Microbiol.
8:89-98.
|
| 40.
|
Pier, G. B.,
M. Grout,
T. S. Zaidi,
J. C. Olsen,
L. G. Johnson,
J. R. Yankaskas, and J. B. Goldberg.
1996.
Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections.
Science
271:64-67[Abstract].
|
| 41.
|
Pilewski, J. M., and R. A. Frizzell.
1999.
Role of CFTR in airway disease.
Physiol. Rev.
79(Suppl.):S215-S255.
|
| 42.
|
Saiman, L., and A. Prince.
1993.
Pseudomonas aeruginosa pili bind to asialoGM1 which is increased on the surface of cystic fibrosis epithelial cells.
J. Clin. Investig.
92:1875-1880.
|
| 43.
|
Saini, L. S.,
S. B. Galsworthy,
M. A. John, and M. A. Valvano.
1999.
Intracellular survival of Burkholderia cepacia complex isolates in the presence of macrophage cell activation.
Microbiology
145:3465-3475[Abstract/Free Full Text].
|
| 44.
|
Sajjan, U.,
M. Corey,
A. Humar,
E. Tullis,
E. Cutz,
C. Ackerley, and J. Forstner.
2001.
Immunolocalization of Burkholderia cepacia in the lungs of cystic fibrosis patients.
J. Med. Microbiol.
50:535-546[Abstract/Free Full Text].
|
| 45.
|
Sajjan, U. S.,
M. Corey,
M. Karmali, and J. F. Forstner.
1991.
Binding of Pseudomonas cepacia to normal human intestinal mucin and respiratory mucin from patients with cystic fibrosis.
J. Clin. Investig.
89:648-656.
|
| 46.
|
Sajjan, U. S., and J. F. Forstner.
1992.
Identification of the mucin-binding adhesin of isolated Pseudomonas cepacia from patients with cystic fibrosis.
Infect. Immun.
60:1434-1440[Abstract/Free Full Text].
|
| 47.
|
Sajjan, U. S., and J. F. Forstner.
1993.
Role of a 22-kilodalton pilin protein in binding of Pseudomonas cepacia to buccal epithelial cells.
Infect. Immun.
61:3157-3163[Abstract/Free Full Text].
|
| 48.
|
Sajjan, U. S.,
L. Sun,
R. Goldstein, and J. F. Forstner.
1995.
Cable (Cbl) type II pili of cystic fibrosis-associated Burkholderia (Pseudomonas) cepacia: nucleotide sequence of the cblA major subunit pilin gene and novel morphology of the assembled appendage fibers.
J. Bacteriol.
177:1030-1038[Abstract/Free Full Text].
|
| 49.
|
Sajjan, U. S.,
F. A. Sylvester, and J. Forstner.
2000.
Cable-piliated Burkholderia cepacia binds to cytokeratin 13 of epithelial cells.
Infect. Immun.
68:1787-1795[Abstract/Free Full Text].
|
| 50.
|
Sajjan, U. S.,
Y. Wu,
G. Kent, and J. Forstner.
2000.
Preferential adherence of cable-piliated B. cepacia to respiratory epithelia of CF knockout mice and human CF lung explants.
J. Med. Microbiol.
49:875-885[Abstract/Free Full Text].
|
| 51.
|
Schwiebert, E. M.,
M. Erik,
J. Dale, and C. Fuller.
1998.
Cystic fibrosis: a multiple exocrinopathy caused by dysfunctions in a multifunctional transport protein.
Am. J. Med.
104:576-590[CrossRef][Medline].
|
| 52.
|
Shi, S.-R.,
M. Key, and K. L. Kalra.
1991.
Antigen retrieval in formalin-fixed paraffin-embedded tissues: an enhanced method for immunohistochemical staining based on microwave oven heating of tissue sections.
J. Histochem. Cytochem.
39:741-748[Abstract].
|
| 53.
|
Smith, D. L.,
L. B. Gumery,
E. G. Smith,
D. E. Stableforth,
M. E. Kaufmann, and T. L. Pitt.
1993.
Epidemic of Pseudomonas cepacia in an adult cystic fibrosis unit: evidence of person-to-person transmission.
J. Clin. Microbiol.
31:3017-3022[Abstract/Free Full Text].
|
| 54.
|
Smith, J. J.,
S. M. Travis,
E. P. Greenberg, and M. J. Welsh.
1996.
Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid.
Cell
85:229-236[CrossRef][Medline].
|
| 55.
|
Snouwaert, J. N.,
K. K. Brigman,
A. M. Latour,
E. Iraj,
U. Schwab,
M. I. Gilmour, and B. H. Koller.
1995.
A murine model of cystic fibrosis.
Am. J. Respir. Crit. Care Med.
151:S59-S64.
|
| 56.
|
Snouwaert, J. N.,
K. K. Brigman,
A. M. Latour,
N. N. Malouf,
R. C. Boucher,
O. Smithies, and B. H. Koller.
1992.
An animal model for cystic fibrosis made by gene targeting.
Science
257:1083-1088[Abstract/Free Full Text].
|
| 57.
|
Sokol, P. A.,
C. Kooi,
R. S. Hodges,
P. Cachia, and D. E. Woods.
2000.
Immunization with a Pseudomonas aeruginosa elastase peptide reduces severity of experimental lung infections due to P. aeruginosa or Burkholderia cepacia.
J. Infect. Dis.
181:1682-1692[CrossRef][Medline].
|
| 58.
|
Speert, D. P.,
B. Steen,
K. Halsey, and E. Kwan.
1999.
A murine model for infection with Burkholderia cepacia with sustained persistence in the spleen.
Infect. Immun.
67:4027-4032[Abstract/Free Full Text].
|
| 59.
|
Sun, L.,
R. Z. Jiang,
S. Steinbach,
A. Holmes,
C. Campanelli,
J. Forstner,
U. Sajjan,
Y. Tan,
M. Riley, and R. Goldstein.
1995.
The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain.
Nat. Med.
1:661-666[CrossRef][Medline].
|
| 60.
|
Tablan, O. C.,
T. L. Chobra,
D. V. Schidlow,
J. W. White,
K. A. Hardy,
P. H. Gilligan,
W. M. Morgan,
L. A. Chow,
W. J. Martone, and W. R. Jarvis.
1985.
Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome.
J. Pediatr.
107:382-387[CrossRef][Medline].
|
| 61.
|
Travis, S. M.,
B. A. Conway,
J. Zabner,
J. J. Smith,
N. N. Anderson,
P. K. Singh,
E. P. Greenberg, and M. J. Welsh.
1999.
Activity of abundant antimicrobials of the human airway.
Am. J. Respir. Cell Mol. Biol.
20:872-879[Abstract/Free Full Text].
|
| 62.
|
Vandamme, P.,
B. Holmes,
M. Vancanneyt,
T. Coenye,
B. Hoste,
R. Coopman,
H. Revets,
S. Lauwers,
M. Gillis,
K. Kersters, and J. R. Govan.
1997.
Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp.
Int. J. Syst. Bacteriol.
47:1188-1200[Abstract/Free Full Text].
|
| 63.
|
Waddell, T. K.,
L. Fialkow,
C. K. Chan,
T. K. Kishimoto, and G. P. Downey.
1994.
Potentiation of the oxidative burst of human neutrophils. A signaling role for L-selectin.
J. Biol. Chem.
269:18485-18491[Abstract/Free Full Text].
|
| 64.
|
Waterer, G. W.,
C. B. Jones, and R. G. Wunderink.
1999.
Bacteremic community-acquired pneumonia in an immunocompetent adult due to Burkholderia cepacia.
Chest
116:1842-1843[Free Full Text].
|
| 65.
|
Zhang, P.,
W. R. Summer,
G. J. Bagby, and S. Nelson.
2000.
Innate immunity and pulmonary host defense.
Immunol. Rev.
173:39-51[CrossRef][Medline].
|
| 66.
|
Zughaier, S. M.,
H. C. Ryley, and S. K. Jackson.
1999.
Lipopolysaccharide (LPS) from Burkholderia cepacia is more active than LPS from Pseudomonas aeruginosa and Stenotrophomonas maltophilia in stimulating tumor necrosis factor alpha from human monocytes.
Infect. Immun.
67:1505-1507[Abstract/Free Full Text].
|
| 67.
|
Zughaier, S. M.,
H. C. Ryley, and S. K. Jackson.
1999.
A melanin pigment purified from an epidemic strain of Burkholderia cepacia attenuates monocyte respiratory burst activity by scavenging superoxide anion.
Infect. Immun.
67:908-913[Abstract/Free Full Text].
|
Infection and Immunity, August 2001, p. 5138-5150, Vol. 69, No. 8
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.8.5138-5150.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Springman, A. C., Jacobs, J. L., Somvanshi, V. S., Sundin, G. W., Mulks, M. H., Whittam, T. S., Viswanathan, P., Gray, R. L., LiPuma, J. J., Ciche, T. A.
(2009). Genetic Diversity and Multihost Pathogenicity of Clinical and Environmental Strains of Burkholderia cenocepacia. Appl. Environ. Microbiol.
75: 5250-5260
[Abstract]
[Full Text]
-
Guilbault, C., Saeed, Z., Downey, G. P., Radzioch, D.
(2007). Cystic Fibrosis Mouse Models. Am. J. Respir. Cell Mol. Bio.
36: 1-7
[Abstract]
[Full Text]
-
Cheretakis, C., Leung, R., Sun, C. X., Dror, Y., Glogauer, M.
(2006). Timing of neutrophil tissue repopulation predicts restoration of innate immune protection in a murine bone marrow transplantation model. Blood
108: 2821-2826
[Abstract]
[Full Text]
-
van Heeckeren, A. M., Schluchter, M. D., Xue, W., Davis, P. B.
(2006). Response to Acute Lung Infection with Mucoid Pseudomonas aeruginosa in Cystic Fibrosis Mice. Am. J. Respir. Crit. Care Med.
173: 288-296
[Abstract]
[Full Text]
-
Rubin, B. B., Downey, G. P., Koh, A., Degousee, N., Ghomashchi, F., Nallan, L., Stefanski, E., Harkin, D. W., Sun, C., Smart, B. P., Lindsay, T. F., Cherepanov, V., Vachon, E., Kelvin, D., Sadilek, M., Brown, G. E., Yaffe, M. B., Plumb, J., Grinstein, S., Glogauer, M., Gelb, M. H.
(2005). Cytosolic Phospholipase A2-{alpha} Is Necessary for Platelet-activating Factor Biosynthesis, Efficient Neutrophil-mediated Bacterial Killing, and the Innate Immune Response to Pulmonary Infection: cPLA2-{alpha} DOES NOT REGULATE NEUTROPHIL NADPH OXIDASE ACTIVITY. J. Biol. Chem.
280: 7519-7529
[Abstract]
[Full Text]
-
Sajjan, U., Keshavjee, S., Forstner, J.
(2004). Responses of Well-Differentiated Airway Epithelial Cell Cultures from Healthy Donors and Patients with Cystic Fibrosis to Burkholderia cenocepacia Infection. Infect. Immun.
72: 4188-4199
[Abstract]
[Full Text]
-
Durie, P. R., Kent, G., Phillips, M. J., Ackerley, C. A.
(2004). Characteristic Multiorgan Pathology of Cystic Fibrosis in a Long-Living Cystic Fibrosis Transmembrane Regulator Knockout Murine Model. Am. J. Pathol.
164: 1481-1493
[Abstract]
[Full Text]
-
Koehler, D. R., Sajjan, U., Chow, Y.-H., Martin, B., Kent, G., Tanswell, A. K., McKerlie, C., Forstner, J. F., Hu, J.
(2003). Protection of Cftr knockout mice from acute lung infection by a helper-dependent adenoviral vector expressing Cftr in airway epithelia. Proc. Natl. Acad. Sci. USA
100: 15364-15369
[Abstract]
[Full Text]
-
Sokol, P. A., Sajjan, U., Visser, M. B., Gingues, S., Forstner, J., Kooi, C.
(2003). The CepIR quorum-sensing system contributes to the virulence of Burkholderia cenocepacia respiratory infections. Microbiology
149: 3649-3658
[Abstract]
[Full Text]
-
Bernier, S. P., Silo-Suh, L., Woods, D. E., Ohman, D. E., Sokol, P. A.
(2003). Comparative Analysis of Plant and Animal Models for Characterization of Burkholderia cepacia Virulence. Infect. Immun.
71: 5306-5313
[Abstract]
[Full Text]
-
Tomich, M., Griffith, A., Herfst, C. A., Burns, J. L., Mohr, C. D.
(2003). Attenuated Virulence of a Burkholderia cepacia Type III Secretion Mutant in a Murine Model of Infection. Infect. Immun.
71: 1405-1415
[Abstract]
[Full Text]
-
Kang, Y., Stein, C. S., Heth, J. A., Sinn, P. L., Penisten, A. K., Staber, P. D., Ratliff, K. L., Shen, H., Barker, C. K., Martins, I., Sharkey, C. M., Sanders, D. A., McCray, P. B. Jr., Davidson, B. L.
(2002). In Vivo Gene Transfer Using a Nonprimate Lentiviral Vector Pseudotyped with Ross River Virus Glycoproteins. J. Virol.
76: 9378-9388
[Abstract]
[Full Text]
-
Chu, K. K., Davidson, D. J., Halsey, T. K., Chung, J. W., Speert, D. P.
(2002). Differential Persistence among Genomovars of the Burkholderia cepacia Complex in a Murine Model of Pulmonary Infection. Infect. Immun.
70: 2715-2720
[Abstract]
[Full Text]
-
Hart, C A., Winstanley, C.
(2002). Persistent and aggressive bacteria in the lungs of cystic fibrosis children. Br Med Bull
61: 81-96
[Abstract]
[Full Text]